000			02139 a2200589 4500
005			20250515044328.0
264		0	_c20070321
008			200703s 0 0 eng d
022			_a1537-1891
024	7		_a10.1016/j.vph.2006.08.415 _2doi
040			_aNLM _beng _cNLM
100	1		_aIskit, Alper B
245	0	0	_aGlibenclamide attenuates the antiarrhythmic effect of endotoxin with a mechanism not involving K(ATP) channels. _h[electronic resource]
260			_bVascular pharmacology _cFeb 2007
300			_a129-36 p. _bdigital
500			_aPublication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
650	0	4	_aAction Potentials _xdrug effects
650	0	4	_aAdenosine Triphosphate _xmetabolism
650	0	4	_aAnimals
650	0	4	_aArrhythmias, Cardiac _xetiology
650	0	4	_aBlood Pressure _xdrug effects
650	0	4	_aCarbamates _xpharmacology
650	0	4	_aCyclohexanes _xpharmacology
650	0	4	_aDisease Models, Animal
650	0	4	_aDrug Interactions
650	0	4	_aEndotoxemia _xchemically induced
650	0	4	_aGlyburide _xpharmacology
650	0	4	_aHeart Atria _xdrug effects
650	0	4	_aHeart Conduction System _xdrug effects
650	0	4	_aLipopolysaccharides _xpharmacology
650	0	4	_aMale
650	0	4	_aMyocardial Ischemia _xcomplications
650	0	4	_aNateglinide
650	0	4	_aPhenylalanine _xanalogs & derivatives
650	0	4	_aPiperidines _xpharmacology
650	0	4	_aPotassium Channel Blockers _xpharmacology
650	0	4	_aPotassium Channels _xdrug effects
650	0	4	_aRats
650	0	4	_aRats, Sprague-Dawley
650	0	4	_aTachycardia, Ventricular _xmetabolism
650	0	4	_aTetraethylammonium
650	0	4	_aTime Factors
650	0	4	_aVentricular Fibrillation _xmetabolism
650	0	4	_aVentricular Premature Complexes _xmetabolism
700	1		_aErkent, Ulkem
700	1		_aErtunc, Mert
700	1		_aGuc, M Oguz
700	1		_aIlhan, Mustafa
700	1		_aOnur, Rustu
773	0		_tVascular pharmacology _gvol. 46 _gno. 2 _gp. 129-36
856	4	0	_uhttps://doi.org/10.1016/j.vph.2006.08.415 _zAvailable from publisher's website
999			_c16639646 _d16639646